Rapporten
Verificerede nyheder om finansiering, hovedkvarterer og ledelse fra verdens mest innovative virksomheder
51 rapporter og tæller
Verastem Oncology Appoints Michael P. Bailey President and CEO
Verastem Oncology appointed director Michael P. Bailey, who spent 16 years at AVEO Pharmaceuticals, as President and CEO effective January 1, 2027, succeeding retiring CEO Daniel Paterson.
Harmony Biosciences Appoints Peter Anastasiou President and Chief Executive Officer
Harmony Biosciences appointed Chief Operating Officer Peter Anastasiou as CEO effective January 1, 2027, succeeding retiring CEO Jeffrey M. Dayno, to lead the company’s next phase of growth.
TETRAPHARM Appoints Rolf Sass Sørensen Chief Executive Officer
TETRAPHARM appointed Rolf Sass Sørensen, formerly of Bavarian Nordic, as CEO to succeed co-founder Martin Rose and lead the Danish biopharmaceutical company’s continued development.
Breye Therapeutics Raises €67.5M Series A for Oral Retinal Disease Drugs
Breye Therapeutics raised an over-subscribed €67.5 million Series A co-led by Mission BioCapital and Novo Holdings to advance danegaptide into a Phase 2 trial.
Altis Labs Raises $25M Series A for AI Clinical-Trial Endpoints
Altis Labs raised a $25 million Series A co-led by OrbiMed and Qiming Venture Partners USA to expand AI endpoints for oncology clinical trials.
Chiesi Appoints David Khougazian Group Chief Executive Officer
Chiesi appointed former Flagship Pioneering executive David Khougazian as Group CEO, succeeding Interim Group CEO Jean-Marc Bellemin, to lead its next phase of innovation-driven growth.
SpyGlass Pharma Opens New Headquarters in Irvine
SpyGlass Pharma opened a 33,000-square-foot headquarters in Irvine, California, on August 27, 2026, moving from its former facility in Aliso Viejo as it prepares for its first product launch.
Vaderis Raises $152M Series B for Rare Vascular Disease Therapy
Vaderis Therapeutics closed a $152 million Series B co-led by Life Sciences at Goldman Sachs Alternatives and TCGX as it began the Phase 3 HEROIC study of engasertib in HHT.
BioNTech Appoints Guido Oelkers Chief Executive Officer
BioNTech’s Supervisory Board appointed Swedish Orphan Biovitrum CEO Guido Oelkers as Chief Executive Officer, succeeding co-founder Ugur Sahin, with Oelkers to take office by February 1, 2027, at the latest.
Viser 9 rapporter • Side 1 • Kategori: all
Hold dig foran markedet
Få ugentlig indsigt leveret til din indbakke. Ingen spam, kun intelligens.